Current concepts about chromium supplementation in type 2 diabetes and insulin resistance

Current Diabetes Reports

Volumn 10, Issue 2, 2010, Pages 145-151

  Wang, Zhong Q ^a   Cefalu, William T ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Chromium supplementation; Insulin resistance; Type 2 diabetes

Indexed keywords

CHROMIUM; CHROMIUM CHLORIDE; CHROMIUM PICOLINATE; GLUCOSE; HEMOGLOBIN A1C; MULTIVITAMIN;

CARBOHYDRATE METABOLISM; CHROMIUM DEFICIENCY; DIET SUPPLEMENTATION; DRUG FORMULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DEFICIENCY; PATIENT SELECTION; REVIEW; SIGNAL TRANSDUCTION; CLINICAL TRIAL (TOPIC); DIET THERAPY; METABOLISM;

CHROMIUM; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; HUMANS; INSULIN RESISTANCE;

EID: 77953621898     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-010-0097-3     Document Type: Review

References (57)

1. Cefalu WT: Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents. Clin Pharmacol Ther 2007, 81:636-649.
2. Riddle MC: Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins and combinations. Endocrinol Metab Clin North Am 2005, 34:77-98.
3. Jeppesen J, Hansen TW, Rasmussen S, et al.: Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol 2007, 49:2112-2119.
4. Haffner SM: Abdominal obesity, insulin resistance, and cardiovascular risk in pre-diabetes and type 2 diabetes. Eur Heart J Suppl 2006, 8(Suppl B):B20-B25.
5. Grundy SM: Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004, 89:2595-2560.
6. Stafylas PC, Sarafidis PA, Lasaridis AN: The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int J Cardiol 2009, 131:298-304.
7. Neuhouser ML: Dietary supplement use by American women: challenges in assessing patterns of use, motives and costs. J Nutr 2003, 133:1992S-1996S.
8. Mehta DH, Gardiner PM, Phillips RS, McCarthy EP: Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions. J Altern Complement Med 2008, 14:1263-1269.
9. Schwarz K, Mertz W: A glucose tolerance factor and its differentiation from factor 3. Arch Biochem Biophys 1957, 72: 515-518.
10. Anderson RA: Chromium in the prevention and control of diabetes. Diabetes Metab 2000, 26:22-27.
11. Schroeder HA: Chromium deficiency in rats: a syndrome simulating diabetes mellitus with retarded growth. J Nutr 1966, 88:439-445.
12. Freund H, Atamian S, Fischer JE: Chromium deficiency during total parenteral nutrition. JAMA 1979, 241:496-498.
13. Anderson RA, Kozlovsky AS: Chromium intake, absorption and excretion of subjects consuming self-selected diets. Am J Clin Nutr 1985, 41:1177-1183.
14. Preuss HG, Anderson RA: Chromium update: examining recent literature 1997-1998. Curr Opin Clin Nutr Metab Care 1998, 1:509-512.
15. Mummel M, Schnell SO: Chromium in metabolic and cardiovascular disease. Horm Metab Res 2007, 39:743-751.
16. Davies S, McLaren Howard J, Hunnisett A, Howard M: Age-related decreases in chromium levels in 51,665 hair, sweat, and serum samples from 40,872 patients: implications for the prevention of cardiovascular disease and type II diabetes mellitus. Metabolism 1997, 46:469-473.
17. Evans GW, Pouchnik DJ: Composition and biological activity of chromium-pyridine carboxylate complexes. J Inorg Biochem 1993, 49:177-187.
18. Cefalu WT, Hu F: Chromium in health and in diabetes. Diabetes Care 2004, 27:2741-2751.
19. Balk EM, Tatsioni A, Lichtenstein AH, et al.: Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 2007, 30:2154-2163.
20. Broadhurst CL, Domenico P: Clinical studies on chromium picolinate supplementation in diabetes mellitus - a review. Diabetes Technol Ther 2006, 8:677-687.
21. Feiner JJ, McNurlan MA, Ferris RE, et al.: Chromium picolinate for insulin resistance in subjects with HIV disease: a pilot study Diabetes Obes Metab 2008, 10:151-158.
22. Lydic ML, McNurlan M, Bembo S, et al.: Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome. Fertil Steril 2006, 86:243-246.
23. Via M, Scurlock C, Raikhelkar J, et al.: Chromium infusion reverses extreme insulin resistance in a cardiothoracic ICU patient. Nutr Clin Pract 2008, 23:325-328.
24. Albarracin CA, Fuqua BC, Evans JL, Goldfine ID: Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev 2008, 24:41-51.
25. Wang ZQ, Qin J, Martin J, et al.: Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation. Metabolism 2007, 56:1652-1655.
26. Cefalu WT, Bell-Farrow AD, Stegner J, et al.: Effect of chromium picolinate on insulin sensitivity in vivo. J Trace Elem Exp Med 1999, 12:71-83.
27. Anderson RA, Cheng N, Bryden NA, et al.: Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997, 46:1786-1791.
28. Martin J, Wang ZQ, Zhang XH, et al.: Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 2006, 29:1826-1832. (Pubitemid 44156637)
29. Gunton JE, Cheung NW, Hitchman R, et al.: Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Diabetes Care 2005, 28:712-713. (Pubitemid 40315337)
30. Kleefstra N, Houweling ST, Bakker SJ, et al.: Chromium treatment has no effect in patients with type 2 diabetes in a Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2007, 30:1092-1096.
31. Kleefstra N, Houweling ST, Jansman FG, et al.: Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2006, 29:521-525.
32. Iqbal N, Cardillo S, Volger S, et al.: Chromium picolinate does not improve key features of metabolic syndrome in obese non-diabetic adults. Metab Syndr Relat Disord 2009, 7:143-150.
33. Komorowski J, Juturu V: Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance: response to Gunton et al. Diabetes Care 2005, 28:1842-1843.
34. Cefalu WT, Rood J, Pinsonat P, et al.: Characterization of the metabolic and physiologic response from chromium supplementation in subjects with type 2 diabetes. Metabolism 2009 Dec 22 [Epub ahead of print].
35. Wang ZQ, Zhang XH, Russell JC, et al.: Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. J Nutr 206, 136:415-420.
36. Cefalu WT, Wang ZQ, Zhang XH, et al.: Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. J Nutr 2002, 132:1107-1114.
37. Anderson RA: Nutritional factors influencing the glucose/insulin system: chromium. J Am Coll Nutr 1997, 16:404-410.
38. Vincent JB: Elucidating a biological role of chromium at a molecular level. Acc Chem Res 2000, 33:503-510.
39. Vincent JB: Mechanisms of chromium action: low-molecular-weight chromium-binding substance. J Am Coll Nutr 1999, 18:6-12.
40. Vincent JB: The biochemistry of chromium. J Nutr 2000, 130:715-718.
41. Brautigan DL, Kruszewski A, Wang H: Chromium and vanadate combination increases insulin-induced glucose uptake by 3T3-L1 adipocytes. Biochem Biophys Res Commun 2006, 347:769-773.
42. Davis CM, Sumrall KH, Vincent JB: A biologically active form of chromium may activate a membrane phosphotyrosine phosphatase (PTP). Biochemistry 1996, 35:12963-12969.
43. Davis CM, Vincent JB: Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry 1997, 36:4382-4385.
44. Wang H, Kruszewski A, Brautigan DL: Cellular chromium enhances activation of insulin receptor kinase. Biochemistry 2005, 44:8167-8175.
45. Horvath EM, Tackett L, McCarthy AM, et al.: Antidiabetogenic effects of chromium mitigate hyperinsulinemia-induced cellular insulin resistance via correction of plasma membrane cholesterol imbalance. Mol Endocrinol 2008, 22:937-950.
46. Pattar GR, Tackett L, Liu P, Elmendorf JS: Chromium picolinate positively influences the glucose transporter system via affecting cholesterol homeostasis in adipocytes cultured under hyperglycemic diabetic conditions. Mutat Res 2006, 610:93-100.
47. Chen G, Liu P, Pattar GR, et al.: Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol Endocrinol 2006, 20:857-870.
48. Goldstein BJ, Zhu L, Hager R, et al.: Enhancement of post-receptor insulin signaling by trivalent chromium in hepatoma cells is associated with differential inhibition of specific protein-tyrosine phosphatases. J Trace Elem Exp Med 2001, 14:393-404.
49. Miranda ER, Dey CS: Effect of chromium and zinc on insulin signaling in skeletal muscle cells. Biol Trace Elem Res 2004, 101:19-36.
50. Dong F, Kandadi MR, Ren J, Sreejayan N: Chromium (D-phenylalanine)3 supplementation alters glucose disposal, insulin signaling, and glucose transporter-4 membrane translocation in insulin-resistant mice. J Nutr 2008, 138:1846-1851.
51. Chen WY, Chen CJ, Liu CH, Mao FC: Chromium supplementation enhances insulin signalling in skeletal muscle of obese KK/HlJ diabetic mice. Diabetes Obes Metab 2009, 11:293-303.
52. Sreejayan N, Dong F, Kandadi MR, et al.: Chromium alleviates glucose intolerance, insulin resistance, and hepatic ER stress in obese mice. Obesity (Silver Spring) 2008, 16:1331-1337.
53. Penumathsa SV, Thirunavukkarasu M, Samuel SM, et al.: Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury. Biochim Biophys Acta 2009, 1792:39-48.
54. Thirunavukkarasu M, Penumathsa SV, Juhasz B, et al.: Niacin-bound chromium enhances myocardial protection from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2006, 291: H820-H826.
55. Jain SK, Rains JL, Croad JL: Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNF-alpha, IL-6, CRP, glycated hemoglobin, triglycerides, and cholesterol levels in blood of streptozotocin-treated diabetic rats. Free Radic Biol Med 2007, 43:1124-1131.
56. Lee YH, White MF: Insulin receptor substrate proteins and diabetes. Arch Pharm Res 2004, 27:361-370.
57. Olefsky JM: Insulin resistance and the pathogenesis of non-insulin dependent diabetes mellitus: cellular and molecular mechanisms. Adv Exp Med Biol 1993,334:129-150.